Table 1.
Immune effects at various time points after initiation of stimulation.
| Stimulus | Read-out | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD40 | CD69 | CD70 | CD80 | CD83 | CD86 | MHC I | MHC II | IL6 | IL8 | Proliferation | IgG | IgM | |
| 24 hours | 2 days | 3 days | 7 days | ||||||||||
| TNP-Ficoll | + | + | + | + | + | + | + | + | + | + | + | + | + |
| TNP-BSA | + | ++ | + | + | + | + | ++ | + | ++ | +++ | ++ | ++ | ++ |
| Anti-IgM | + | ++ | + | + | ++ | + | + | + | + | + | + | + | NA |
| Anti-IgM + IL4 |
++ | +++ | + | + | +++ | + | + | + | +++ | + | +++ | ++ | NA |
| Anti-CD40 | NA | ++ | + | + | ++ | ++ | + | + | + | + | + | ++ | + |
| Anti-CD40 + IL4 |
NA | +++ | + | ++ | +++ | +++ | + | + | +++ | + | +++ | ++ | +++ |
| Anti-CD40 + IL21 |
NA | +++ | + | ++ | + | +++ | ++ | + | + | + | +++ | +++ | +++ |
| IL21 | + | +++ | + | + | + | + | + | + | + | + | + | ++ | ++ |
| LPS | + | + | + | + | ++ | + | + | + | ++ | ++ | + | + | + |
| Resiquimod | +++ | +++ | ++ | ++ | ++ | +++ | + | + | +++ | +++ | ++ | ++ | +++ |
| ODN2006 | +++ | +++ | ++ | +++ | +++ | +++ | ++ | + | +++ | ++ | +++ | +++ | +++ |
| Pansorbin + IL2 + IL10 |
+ | +++ | +++ | ++ | +++ | +++ | + | + | +++ | +++ | +++ | +++ | +++ |
| Pokeweed | + | + | + | + | + | + | + | + | ++ | +++ | ++ | + | +++ |
In four independent experiments, different in vitro stimulatory conditions were tested on freshly isolated human B cells; the strength of their effect on proliferation, Ig and cytokine production, and expression of cell surface markers is represented in the table (+++ = strong effect, ++ = moderate effect, + = weak effect, and NA = not analysed). For the definition of weak, moderate, or strong effect, see Section 2.